Lonza Signs Deal with LegoChem Biosciences to Provide Pre-clinical Material of Therapeutic Compound

Lonza says it has signed an agreement with biotech company LegoChem Biosciences (Daejeon, Korea), for the custom material production of a monoclonal antibody that will be used for in vivo proof of concept studies for their technology platform development. Lonza will produce pre-clinical material using its Light Path discovery services at its applied protein services facility at Cambridge, U.K., under the deal. Lonza’s Light Path discovery services “were specifically designed with the demands of pre-clinical assessment in mind,” says Janet White...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers